{"id":"calcipotriol-plus-hydrocortisone-ointment","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or burning at application site"},{"rate":null,"effect":"Hypercalcemia (with excessive use)"},{"rate":null,"effect":"Local skin atrophy (from corticosteroid component)"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":{"chemblId":"CHEMBL4563773","moleculeType":"Unknown","molecularWeight":"412.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcipotriol acts as a selective vitamin D3 receptor agonist, normalizing keratinocyte differentiation and reducing hyperproliferation characteristic of psoriasis. Hydrocortisone provides rapid anti-inflammatory and immunosuppressive effects through glucocorticoid receptor activation. The combination leverages complementary mechanisms: the vitamin D analogue provides disease-modifying activity while the corticosteroid delivers faster symptomatic relief.","oneSentence":"Calcipotriol (a vitamin D analogue) reduces skin cell proliferation and promotes differentiation, while hydrocortisone (a corticosteroid) suppresses inflammation and immune responses in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:42.286Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis (plaque psoriasis)"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT00691002","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-05","conditions":"Psoriasis Vulgaris","enrollment":1245},{"nctId":"NCT00640822","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-02","conditions":"Psoriasis Vulgaris","enrollment":782},{"nctId":"NCT01007591","phase":"PHASE3","title":"A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-10","conditions":"Psoriasis Vulgaris","enrollment":40},{"nctId":"NCT00704262","phase":"PHASE2","title":"Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-05","conditions":"Psoriasis Vulgaris","enrollment":33},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Calcipotriol plus hydrocortisone ointment","genericName":"Calcipotriol plus hydrocortisone ointment","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcipotriol (a vitamin D analogue) reduces skin cell proliferation and promotes differentiation, while hydrocortisone (a corticosteroid) suppresses inflammation and immune responses in the skin. Used for Psoriasis (plaque psoriasis), Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}